<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardiovascular disease risk assessment for primary prevention: Risk calculators</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardiovascular disease risk assessment for primary prevention: Risk calculators</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardiovascular disease risk assessment for primary prevention: Risk calculators</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter WF Wilson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2458824542"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atherosclerotic cardiovascular disease (ASCVD) is common in the general population, affecting the majority of adults past the age of 60 years. As a diagnostic category, ASCVD includes four major areas:</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary heart disease (CHD) manifested by fatal or nonfatal myocardial infarction, angina pectoris, and/or heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrovascular disease manifested by fatal or nonfatal stroke and transient ischemic attack</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral artery disease manifested by intermittent claudication and critical limb ischemia</p><p class="bulletIndent1"><span class="glyph">●</span>Aortic atherosclerosis and thoracic or abdominal aortic aneurysm</p><p></p><p>Although CHD is the most common manifestation of ASCVD, CHD represents only approximately 50 percent of the total number of first ASCVD events. The lifetime risk of CHD was illustrated in a study of 7733 participants, age 40 to 94, in the Framingham Heart Study who were initially free of CHD [<a href="#rid1">1</a>]. The lifetime risk for individuals at age 40 was 49 percent in males and 32 percent in females. Even those who were apparently free from disease at age 70 had a lifetime risk of 35 percent and 24 percent in males and females, respectively. The lifetime risk of CHD varies importantly with the aggregate risk factor burden [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach", section on 'Lifetime risk'</a>.)</p><p>While a general estimate of the relative risk for ASCVD can be approximated by counting the number of traditional risk factors present in a patient, a more precise estimation of the absolute risk for a first ASCVD event is desirable when making treatment recommendations for a specific individual. This topic discusses the various ASCVD risk models available for use in patients. Our approach to ASCVD risk assessment for primary prevention, including which patients should undergo ASCVD risk assessment, the approach to assessing risk, and the implications of the estimate risk on preventive therapies, is presented separately, as are discussions of the specific approach to the primary prevention treatment of various risk factors. (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a> and  <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease", section on 'CVD risk assessment'</a>.)</p><p class="headingAnchor" id="H2965917609"><span class="h1">MULTIVARIATE RISK MODELS</span><span class="headingEndMark"> — </span>A number of multivariate risk models have been developed for estimating the risk of initial ASCVD events in apparently healthy, asymptomatic individuals based upon assessment of multiple variables  (<a class="graphic graphic_table graphicRef115308" href="/z/d/graphic/115308.html" rel="external">table 1</a>). While all of the risk models have advantages and disadvantages, no single risk model will be appropriate for all patients [<a href="#rid3">3,4</a>]. The choice of a specific risk model for ASCVD risk assessment should be individualized based on patient-specific characteristics (eg, age, sex, ethnicity). Most experts feel that the use of risk models that predict hard ASCVD events (ie, death, myocardial infarction [MI], stroke) are preferred over those that include other endpoints (ie, revascularization).</p><p class="headingAnchor" id="H525914099"><span class="h2">Typical variables used in ASCVD estimators</span><span class="headingEndMark"> — </span>Prediction of ASCVD is based on a set of risk variables that are usually assessed in the outpatient setting. Most estimators use the variables of age, gender, total cholesterol, HDL cholesterol, systolic blood pressure, diabetes mellitus (DM), and current smoking  (<a class="graphic graphic_table graphicRef115308" href="/z/d/graphic/115308.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1574003748"><span class="h2">Other variables included in various ASCVD estimators</span><span class="headingEndMark"> — </span>A variety of factors beyond traditional measures are used in risk estimators  (<a class="graphic graphic_table graphicRef115308" href="/z/d/graphic/115308.html" rel="external">table 1</a>). A brief summary includes: </p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure treatment (ATP III 2002, Framingham Risk Score 2008, American College of Cardiology/American Heart Association [ACC/AHA] 2013, MESA 2015, China-PAR 2016).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of CVD (SCORE CVD Death 2003, Reynolds Females 2007, Reynolds Males 2008, JBS3 2014, MESA 2015, Astro-CHARM 2018).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid arthritis (JBS3 2014).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Body mass index (QRISK 2007, JBS3 2014).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Waist circumference (China-PAR 2016).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Geographic region (SCORE CVD Death 2003, JBS3 2014).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urbanization (China-PAR 2016).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C-reactive protein (Reynolds Females 2007, Reynolds Males 2008, Astro-CHARM 2018).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic kidney disease (JBS3 2014).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation (JBS3 2014).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipid lowering treatment (MESA 2015).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coronary artery calcium score (MESA 2015, Astro-CHARM 2018).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statin use at baseline (VA ASCVD 2020).</p><p></p><p class="headingAnchor" id="H2203970888"><span class="h2">Key features of the most commonly used risk calculators</span><span class="headingEndMark"> — </span>A variety of risk models and calculators have been derived over the years, but a select few have been most commonly used in clinical practice. Among the many reasons why specific risk calculators are more popular are ease of use, applicability to a clinician’s patient population, outcomes measured, and professional society recommendations. Some key features of the most commonly utilized risk calculators include:</p><p class="bulletIndent1"><span class="glyph">●</span>Framingham risk score (1998) and ATP III hard CHD risk score (2001) – The 1998 Framingham model used traditional risk factor categories and included data mostly from the 1970s and 1980s with long-term follow-up. Outcomes are limited exclusively to CHD. The 1998 Framingham model was the foundation for the 2002 ATP III hard CHD risk score and ATP III guidelines, which were developed in the United States. This was the primary risk score used in the United States from 2002 to 2013. (See <a class="local">'Framingham risk score (1998)'</a> below and <a class="local">'ATP III hard CHD risk score (2002)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SCORE CVD death risk score (2003) – The 2003 SCORE CVD risk model included data from a variety of European countries, and included a hard endpoint of CVD death but did not address nonfatal CVD events or morbidity. The 2003 SCORE CVD risk calculator has been recommended for use in Europe beginning with the 2007 European Guidelines [<a href="#rid5">5</a>]. (See <a class="local">'SCORE CVD death risk score (2003)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ACC/AHA pooled cohort hard ASCVD risk score (2013) – The 2013 ACC/AHA pooled cohort hard ASCVD risk score was developed from several United States cohorts, and includes different calculators for White individuals and for Black individuals. Outcomes are limited to both fatal and nonfatal CHD and stroke. Beginning in 2013, the ACC/AHA pooled cohort hard ASCVD risk score was recommended for use in the United States [<a href="#rid6">6,7</a>]. (See <a class="local">'ACC/AHA pooled cohort hard ASCVD risk calculator (2013), updated algorithm 2018'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>QRISK, QRISK2, and JBS3 (2014) – The QRISK and QRISK2 ASCVD risk calculators used the Framingham (1998) and ATP III (2002) models as a baseline, then added multiple additional medical, ethnic, and socioeconomic variables. JBS3 included the same variables as QRISK/QRISK2 but extended the risk prediction from 10 years to 30 years, and included a variety of fatal and nonfatal ASCVD endpoints. These models were developed in the United Kingdom and, beginning in 2014, are recommended for use by the Joint British Guidelines [<a href="#rid8">8</a>]. (See <a class="local">'JBS3 risk score (2014)'</a> below.)</p><p></p><p class="headingAnchor" id="H1049029831"><span class="h2">Framingham risk score (1998)</span><span class="headingEndMark"> — </span>The original Framingham risk score (1998), published in 1998, was derived from a largely White population of European descent [<a href="#rid9">9</a>]. Subsequent studies have suggested that the Framingham risk score performs well for prediction of CHD events in Black and White females and males [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2246442260"><span class="h3">Endpoints assessed in Framingham CHD risk score (1998)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Unstable angina</p><p class="bulletIndent1"><span class="glyph">●</span>Stable angina</p><p></p><p class="headingAnchor" id="H3848185242"><span class="h2">ATP III hard CHD risk score (2002)</span><span class="headingEndMark"> — </span>The Framingham risk score was modified (2002) by the third Adult Treatment Panel (ATP III) for use in their recommendations for screening for and treatment of dyslipidemia [<a href="#rid11">11</a>]. The modifications include elimination of diabetes from the algorithm, since it was considered to be a CHD equivalent; broadening of the age range; and inclusion of hypertension treatment and age-specific points for smoking and total cholesterol.</p><p class="headingAnchor" id="H2099670809"><span class="h3">Endpoints assessed in ATP III hard CHD risk score (revised 2002)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p></p><p class="headingAnchor" id="H3623707360"><span class="h2">Framingham general risk score (2008)</span><span class="headingEndMark"> — </span>The original 1998 and revised 2002 Framingham risk scores do not include all of the potential manifestations and adverse consequences of atherosclerosis, such as stroke, transient ischemic attack, claudication, and heart failure (HF; although manifestations of aortic atherosclerosis were omitted). These patient-important vascular outcomes were included in the development of the 2008 Framingham general cardiovascular risk score, which was shown to have reliable predictive ability (<a class="calc calc_professional" href="/z/d/html/13468.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/13469.html" rel="external">calculator 2</a>) [<a href="#rid12">12</a>]. The estimated risk of developing a cardiovascular event will be higher with this risk score than with those that predict only CHD events.</p><p class="headingAnchor" id="H4194474227"><span class="h3">Endpoints assessed in Framingham general risk score (2008)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary insufficiency or angina</p><p class="bulletIndent1"><span class="glyph">●</span>Fatal or nonfatal ischemic or hemorrhagic stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Transient ischemic attack</p><p class="bulletIndent1"><span class="glyph">●</span>Intermittent claudication</p><p class="bulletIndent1"><span class="glyph">●</span>HF</p><p></p><p class="headingAnchor" id="H242847987"><span class="h2">SCORE CVD death risk score (2003)</span><span class="headingEndMark"> — </span>SCORE, which is recommended in the 2007 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice, included data on more than 200,000 patients pooled from cohort studies in 12 European countries [<a href="#rid5">5,13</a>]. A unique aspect of SCORE is that separate risk scores were calculated for high- and low-risk regions of Europe. The predictive value of SCORE was high in each component study cohort.</p><p>SCORE differs from the earlier Framingham risk models (and others) in two important ways: it estimates the 10-year risk of any first fatal atherosclerotic event (eg, stroke or ruptured abdominal aneurysm), not just CHD-related deaths, and it estimates CVD mortality.</p><p class="headingAnchor" id="H1207675272"><span class="h3">Endpoints assessed in SCORE CVD death risk estimator (2003)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CVD death (including CHD, arrhythmia, HF, stroke, aortic aneurysm, and peripheral vascular disease)</p><p></p><p class="headingAnchor" id="H2581167954"><span class="h2">QRISK and QRISK2</span><span class="headingEndMark"> — </span>The QRISK and the updated QRISK2 algorithms were developed to predict cardiovascular risk in patients from different ethnic groups living in England and Wales [<a href="#rid14">14,15</a>]. The QRISK2 algorithm included risk predictors used in the modified Framingham/ATP III model, as well as ethnicity, socioeconomic status, family history, and other medical variables such as diabetes, chronic renal disease, atrial fibrillation, and rheumatoid arthritis. QRISK2 more accurately identified those at risk than the modified Framingham/ATP III model in this population.</p><p class="headingAnchor" id="H2360775492"><span class="h3">Endpoints assessed in QRISK ASCVD risk estimator (2007)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary insufficiency or angina</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary revascularization</p><p class="bulletIndent1"><span class="glyph">●</span>Fatal or nonfatal stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Transient ischemic attack</p><p class="bulletIndent1"><span class="glyph">●</span>Intermittent claudication</p><p></p><p class="headingAnchor" id="H1342664329"><span class="h2">Reynolds risk score for females (2007)</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.reynoldsriskscore.org%2F&amp;token=tqDeH8bQ5v4BAR8DY6KRIw%2BT89Z9Yl5nAE%2FlSF4mWbTNjt3bxpIMRjHyd%2B5P6NQh&amp;TOPIC_ID=114029" target="_blank">Reynolds risk score</a> for females was developed from a prospective cohort of nearly 25,000 American females without diabetes [<a href="#rid16">16</a>]. The primary differences between the Reynolds risk score and most other risk estimations are the inclusion of family history of MI and high-sensitivity C-reactive protein (hs-CRP) as variables in the risk calculator. (See  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H449523004"><span class="h3">Endpoints assessed in Reynolds risk score for females (2007)</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary revascularization</p><p></p><p class="headingAnchor" id="H22988082"><span class="h2">Reynolds risk score for males (2008)</span><span class="headingEndMark"> — </span>Similar to the Reynolds risk score for females, the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.reynoldsriskscore.org%2F&amp;token=tqDeH8bQ5v4BAR8DY6KRIw%2BT89Z9Yl5nAE%2FlSF4mWbTNjt3bxpIMRjHyd%2B5P6NQh&amp;TOPIC_ID=114029" target="_blank">Reynolds risk score</a> for males was developed from a prospective cohort of over 10,000 American males without diabetes and also included family history of MI and hs-CRP as variables in the risk calculator [<a href="#rid17">17</a>]. Unlike the Reynolds risk score for females, hemoglobin A1c level was not included as a variable in the Reynolds risk score for males. (See  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H3021113191"><span class="h3">Endpoints assessed in Reynolds risk score for males (2008)</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary revascularization</p><p></p><p class="headingAnchor" id="H3292929470"><span class="h2">ACC/AHA pooled cohort hard ASCVD risk calculator (2013), updated algorithm 2018</span><span class="headingEndMark"> — </span>Several cohorts of patients were used to develop the 2013 ACC/AHA cardiovascular risk calculator (<a class="calc calc_professional" href="/z/d/html/107063.html" rel="external">calculator 3</a>), the first risk model to include data from large populations of both White and Black American patients [<a href="#rid6">6</a>]. The model includes the same parameters as the 2008 Framingham general ASCVD model, but in contrast to the 2008 Framingham model includes only hard endpoints (fatal and nonfatal MI and stroke). However, while the calculator appears to be well-calibrated in some populations similar to those for which the calculator was developed (REGARDS), it has not been as accurate in other populations (Rotterdam) [<a href="#rid7">7,18-20</a>]. </p><p>A potential limitation of the ACC/AHA calculator is that family history of premature ASCVD is not included in the model. This may underestimate risk in patients with very strong family histories of cardiovascular events. Additionally, the ACC/AHA includes DM only as a yes/no question. Issues that may affect risk with DM include patient age, sex, other cardiovascular risk factors, duration of DM, and whether the patient has type 1 or type 2 DM. A downloadable calculator that incorporates these variables is available for patients with type 2 DM from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.dtu.ox.ac.uk%2Friskengine%2F&amp;token=5BtIyUZxwqlJItrM5wN8D0PImCoGpjt3JWC0TiIhDUiEwuyuJIw7%2BBNz8mFW2B24&amp;TOPIC_ID=114029" target="_blank">UK Prospective Diabetes Study</a>.</p><p class="headingAnchor" id="H3691310516"><span class="h3">Endpoints assessed in ACC/AHA pooled cohort hard ASCVD risk calculator (2013), updated 2018</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Fatal stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal stroke</p><p></p><p>In 2018, this algorithm was updated [<a href="#rid21">21</a>]. The basic ASCVD risk scoring was maintained, but intermediate risk scores were redefined.</p><p class="headingAnchor" id="H2653400331"><span class="h2">JBS3 risk score (2014)</span><span class="headingEndMark"> — </span>The Joint British Societies (JBS) released a new risk calculator in 2014 which is based on the QRISK lifetime cardiovascular risk calculator and incorporates many of the same variables from the original QRISK and QRISK2 scores [<a href="#rid8">8</a>]. However, the JBS3 risk calculator extends the assessment of risk beyond the 10-year window of most prior risk estimators and allows for the estimate of "heart age" and the assessment of risk over longer intervals (eg, 50 years for a 45-year-old patient, 30 years for a 65-year-old patient, etc). The JBS calculator also allows for the estimated impact of lifestyle modifications on future risk (ie, the impact of smoking cessation on ASCVD risk), but these data are from statistical models and have not been externally validated. A link to this calculator can be found at the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.jbs3risk.com%2F&amp;token=q4x73gH5GHofqhz2GZci79XkFXjU4eayYjty7BiKu6evALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=114029" target="_blank">JBS3 risk website</a>.</p><p class="headingAnchor" id="H649642670"><span class="h3">Endpoints assessed in JBS3 risk estimator (2014)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary insufficiency or angina</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary revascularization</p><p class="bulletIndent1"><span class="glyph">●</span>Fatal or nonfatal stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Transient ischemic attack</p><p class="bulletIndent1"><span class="glyph">●</span>Intermittent claudication</p><p></p><p class="headingAnchor" id="H4290213398"><span class="h2">MESA risk score (2015)</span><span class="headingEndMark"> — </span>The Multi-Ethnic Study of Atherosclerosis (MESA) published a risk score in 2015, which was validated in two separate prospective cohort groups [<a href="#rid22">22</a>]. While many of the traditional risk factors are also part of the MESA risk score, this risk estimator also includes multiple ethnic backgrounds (<a class="calc calc_professional" href="/z/d/html/107280.html" rel="external">calculator 4</a>). The MESA risk score also incorporates coronary artery calcium (CAC) score to further classify the patients, although an estimate of risk can also be made without entering the CAC score for patients. </p><p class="headingAnchor" id="H2468771961"><span class="h3">Endpoints assessed in MESA risk score (2015)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Resuscitated cardiac arrest</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary revascularization in patient with angina</p><p></p><p class="headingAnchor" id="H301276995"><span class="h2">China-PAR risk predictor (2016)</span><span class="headingEndMark"> — </span>The Predication for ASCVD Risk in China (China-PAR) project published a risk score in 2016, which was validated in two separate prospective Chinese cohort groups [<a href="#rid23">23</a>]. While many of the traditional risk factors are part of the China-PAR risk estimator, this risk estimator also includes waist circumference and geographic region within China for both males and females, as well as urbanization and family history for males. The China-PAR risk estimator was found to be more accurate for persons living in China than the ACC/AHA pooled cohort equations, which tended to overestimate risk in Chinese males while underestimating risk in Chinese females. The China-PAR model has yet to be evaluated for adults living outside China.</p><p class="headingAnchor" id="H1590123570"><span class="h3">Endpoints assessed in China-PAR (2016)</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Fatal or nonfatal stroke</p><p></p><p class="headingAnchor" id="H1057745931"><span class="h2">PREDICT CVD risk predictor (2018)</span><span class="headingEndMark"> — </span>The PREDICT CVD risk predictor was developed in a multiethnic New Zealand population of over 400,000 patients with no prior history of cardiovascular or kidney disease who were recruited between 2002 and 2015 [<a href="#rid24">24</a>]. The PREDICT CVD risk predictor includes many of the traditional risk factors, along with predictors based on family history and ethnicity. In contrast to nearly all other risk predictors that offer estimates of 10-year or lifetime CVD risk, the PREDICT CVD risk predictor estimates risk at five years. The PREDICT CVD risk predictor was significantly more accurate in this New Zealand population than the ACC/AHA pooled cohort equation, which overestimated the risk by between 40 and 60 percent.</p><p class="headingAnchor" id="H3898065827"><span class="h3">Endpoints assessed in PREDICT (2018)</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular death (including MI, stroke, or atherosclerotic aneurysm)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>CHD revascularization, both surgical and percutaneous</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Transient ischemic attack</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral vascular disease including revascularization procedures</p><p class="bulletIndent1"><span class="glyph">●</span>HF and cardiomyopathy (unless specified as nonischemic in origin)</p><p></p><p class="headingAnchor" id="H785239795"><span class="h2">Astro-CHARM risk calculator</span><span class="headingEndMark"> — </span>The Astro-CHARM ASCVD risk calculator was derived from study participants in three cohorts (MESA, Dallas Heart Study, and Prospective Army Coronary Calcium Project; 7382 persons; 55 percent male; 45 percent White individuals) in which family history, coronary artery calcium score, and high-sensitivity CRP were obtained at baseline and incorporated into the risk calculator, along with the traditional risk factors [<a href="#rid25">25</a>]. While showing a small improvement in net reclassification of risk, the Astro-CHARM study involved relatively young persons (mean age 51 years) at relatively low risk of CVD (only 55 events seen among 2057 patients in the validation cohort).</p><p class="headingAnchor" id="H2331790166"><span class="h3">Endpoints assessed in Astro-CHARM</span></p><p class="bulletIndent1"><span class="glyph">●</span>CHD death</p><p class="bulletIndent1"><span class="glyph">●</span>Nonfatal MI</p><p class="bulletIndent1"><span class="glyph">●</span>Fatal or nonfatal stroke</p><p></p><p class="headingAnchor" id="H19828001"><span class="h2">VA-ASCVD risk calculator</span><span class="headingEndMark"> — </span>The five-year risk of developing an initial atherosclerotic cardiovascular disease (ASCVD) event or ASCVD mortality was estimated in 1.6 million US veterans. The 2013 Pooled Cohort Equations overestimated ASCVD risk approximately twofold for each group: White females, Black females, White males, and Black males. Baseline statin therapy was associated with a 7 percent lower relative risk of ASCVD and a 25 percent lower relative risk for ASCVD death [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H2318836311"><span class="h3">Endpoints assessed in VA-ASCVD</span></p><p class="bulletIndent1"><span class="glyph">●</span>MI</p><p class="bulletIndent1"><span class="glyph">●</span>Fatal or nonfatal stroke</p><p class="bulletIndent1"><span class="glyph">●</span>ASCVD death</p><p></p><p class="headingAnchor" id="H1381520294"><span class="h2">Comparison among different risk scores</span><span class="headingEndMark"> — </span>An important component of multivariate risk models for the estimation of ASCVD risk is that many of the risk factors (eg, age, hypertension, serum LDL-cholesterol) are recognized as producing a graded increase in risk  (<a class="graphic graphic_figure graphicRef55353" href="/z/d/graphic/55353.html" rel="external">figure 1</a>) [<a href="#rid27">27</a>]. In addition, these models estimate risk of an individual patient over the next 10 years, even though the risk models have been derived from large population-based studies.</p><p>Several studies have suggested that the Framingham criteria either overestimate or underestimate the risk of initial CHD events in other populations such as Japanese American and Hispanic males, Chinese patients, Native American females, individuals in various European countries (eg, the United Kingdom and France), and African American males and females, as well as individuals older than age 85 years [<a href="#rid3">3-5,10,13,23,24,28-35</a>]. These differences are partly explained by the research methods used, adjudication procedures, time intervals studied, and calendar year of the baseline evaluations. Multiple models, including SCORE and QRISK2, have been developed in an attempt to provide better predictive accuracy for individuals in European countries [<a href="#rid5">5,13-15,31-33</a>].</p><p>How a risk score performs is largely dependent on population characteristics along with the presence or absence of primary preventive therapies to address relevant risk factors. </p><p class="bulletIndent1"><span class="glyph">●</span>In an attempt to assess the performance of risk scores in a diverse population, five risk scores (1998 Framingham, 2002 ATP III, 2008 Framingham, Reynolds risk score, and 2013 ACC/AHA score) were calculated for 4227 racially diverse participants of the MESA cohort (42 percent White, 26 percent Black, 20 percent Hispanic, 12 percent Chinese) ages 50 to 74 years and without ASCVD or diabetes at baseline (follow-up 10.2 years) [<a href="#rid3">3</a>]. When comparing the predicted and observed rates of ASCVD, four of the five risk scores significantly overestimated the 10-year ASCVD risk (between 25 and 115 percent), with only the Reynolds risk score slightly underestimating risk (3 percent underestimation). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate study comparing the 2013 ACC/AHA calculator with the ATP III risk estimator among 2435 participants in the Framingham offspring and third-generation cohorts who were followed for over nine years, the 2013 ACC/AHA calculator identified significantly more patients as statin eligible and more accurately identified patients who were at risk for incident ASCVD [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate study assessing the accuracy of the 2013 ACC/AHA calculator in six cohorts (the original four used to develop the pool cohort equations plus MESA and the Jackson Heart study) found that the 2013 ACC/AHA calculator overestimated risk by an average of 20 percent [<a href="#rid37">37</a>].</p><p></p><p>A variety of issues may underlie these differences, including secular changes in risk factors, greater use of cardiovascular prevention medicines and strategies over the past two decades, and a general decline in ASCVD morbidity and mortality in more recent times. The exact reasons for overestimation of risk are not known. In addition to these findings reinforcing the importance of being familiar with multiple risk scores and choosing the most applicable risk score for each individual patient (based upon the patient's unique characteristics), the potential for overestimation of ASCVD risk should be recognized in the discussion of risk and the decision-making process regarding therapies aimed at primary prevention.</p><p class="headingAnchor" id="H1833017839"><span class="h2">Limitations of current vascular disease prediction models</span><span class="headingEndMark"> — </span>The following represent important limitations to current risk models:</p><p class="bulletIndent1"><span class="glyph">●</span>Risk assessments that stratify patients according to the number of defined risk factors can identify high-risk persons, but they tend to falsely reassure persons deemed to be at low risk who may have multiple marginal abnormalities [<a href="#rid2">2,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Prevalence and impact of cardiovascular risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk models identify patients who are more or less likely to develop ASCVD within a defined period (eg, 10 years for CHD in the Framingham model). This approach does not consider lifetime risk, which might be substantially higher and amenable to aggressive risk factor reduction [<a href="#rid2">2,39-41</a>]. However, the 2013 ACC/AHA guideline on the assessment of cardiovascular risk calculators does offer an estimate of lifetime risk [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach", section on 'Lifetime risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some risk scores have been found to overestimate 10-year risk of ASCVD. (See <a class="local">'Comparison among different risk scores'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most ASCVD risk scores do not account for an individual’s socioeconomic status or geographic/neighborhood location, which can significantly impact the accuracy of one’s estimated ASCVD risk [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is significant variability in predicted risk when multiple risk scores are applied to the same population, particularly when used in a population that is different from the validation cohort of the risk score [<a href="#rid3">3,4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The severity and frequency of the first vascular disease event has decreased over the last 40 years [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relative effects of traditional risk factors differ according to the vascular disease outcome being evaluated [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some risk models do not include patient-important ASCVD outcomes such as stroke, HF, or development of symptomatic peripheral artery disease.</p><p></p><p class="headingAnchor" id="H619877922"><span class="h1">ADDITIONAL RISK ASSESSMENT</span><span class="headingEndMark"> — </span>For most patients who require ASCVD risk assessment, we do not routinely perform additional testing above and beyond that which is part of the standard risk calculator used (eg, lipid values, blood pressure reading, etc). However, in select patients, such as those whose estimated risk is near a threshold to treat (or not treat) or patients whose risk factor(s) may not be adequately included in the standard risk calculators (eg, strong family history of premature ASCVD in multiple relatives), additional risk assessment may be helpful to guide treatment decisions.</p><p>There is likely a small added benefit to assessing genetic information for the purpose of ASCVD risk stratification, and cost benefit of these approaches are not well established [<a href="#rid44">44</a>].</p><p>The use of evaluations beyond traditional risk factor assessment has been considered by multiple major professional societies:</p><p class="bulletIndent1"><span class="glyph">●</span>In 2018, the United States Preventive Service Task Report issued a recommendation statement (and associated evidence report) in which it concluded that there was insufficient evidence to assess the balance of benefits and harms of adding high-sensitivity C-reactive protein (hs-CRP), coronary artery calcium (CAC) score, or ankle-brachial index (ABI) to standard risk assessment [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 2013, the American College of Cardiology/American Heart Association issued a Risk Assessment report in conjunction with new cholesterol guidelines [<a href="#rid6">6</a>]. The opinion of this expert committee was that quantitative risk assessment should occur first, and if a risk-based treatment decision is uncertain, assessment of family history of ASCVD, hs-CRP, CAC score, or ABI may be considered to inform treatment decision making. The committee did not recommend routine measurement of carotid intima-media thickness for risk assessment for a first ASCVD event. The committee also did not recommend use of apolipoprotein B (apoB), chronic kidney disease, albuminuria, or cardiorespiratory fitness evaluation for risk assessment for a first ASCVD event.</p><p></p><p>In a 2016 study that assessed the impact of 13 negative risk markers (including CAC score of 0, normal carotid intima-media thickness, CRP &lt;2 mg/L, B-type natriuretic peptide &lt;100 pg/mL, and negative family history, among others) on the future risk of all ASCVD and CHD in 6814 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) without known ASCVD at baseline, a CAC score of 0 was the strongest modulator of future risk and had the greatest impact on net reclassification of risk [<a href="#rid47">47</a>]. In a 2020 study which assessed the impact of baseline CAC score and high-sensitivity cardiac troponin (hs-cTnT) levels on ASCVD risk among the MESA cohort, patients with undetectable hs-cTnT levels had similar rates of incident ASCVD as did patients with CAC = 0 (5.2 versus 5.0 per 1000 person-years, respectively), while patients with both undetectable hs-cTnT and CAC = 0 had the lowest event rates (2.8 per 1000 person-years) [<a href="#rid48">48</a>]. Future studies that incorporate additional risk factors into the traditional risk models may further guide clinicians in the assessment of individual ASCVD risk. (See  <a class="medical medical_review" href="/z/d/html/5297.html" rel="external">"Coronary artery calcium scoring (CAC): Overview and clinical utilization", section on 'Patients we screen'</a>.)</p><p>Specific lipid subfractions contribute differently to predictions of overall CHD risk (see  <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis"</a>). Lipid subfractions are generally classified by relative density, with low-density lipoprotein (LDL) and high-density lipoprotein (HDL) most commonly measured. Many additional measurements are available, including further subfractions of LDL based on density [<a href="#rid49">49</a>] and measurement of various apolipoproteins (apo) A-1 and B. </p><p>There are numerous studies examining the power of each of these various lipoproteins in predicting CHD risk. There is generally a consensus that non-HDL cholesterol (total cholesterol minus HDL-C) or the total cholesterol to HDL-C ratio is a better predictor of CHD risk than LDL cholesterol (LDL-C) alone [<a href="#rid50">50,51</a>]. The literature is largely consistent on this matter:</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of data from the Framingham study, the ratio of total cholesterol to HDL-C significantly affected the risk for CHD events (hazard ratio [HR] 1.39, 95% CI 1.22-1.58), while LDL-C was not a significant predictor of such events (HR 1.11, CI 0.97-1.27) [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an individual patient meta-analysis of 302,430 people, the ratio of non-HDL-C to HDL-C was a better predictor of CHD risk than LDL-C (HR 1.49 versus 1.38) [<a href="#rid53">53</a>]. The authors concluded that measurement of total cholesterol and HDL-C was simpler and provided more accurate risk estimation than measuring LDL-C.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study examining the predictive power of lipid levels on CHD events in patients on statins, the predictive power of non-HDL-C was superior to that of LDL-C (p = 0.002) [<a href="#rid54">54</a>].</p><p></p><p>While LDL subfractions may perform better than LDL-C alone, they have not been adequately assessed relative to existing risk scores [<a href="#rid55">55</a>]. The lack of additional predictive power of LDL-C is reflected in most predictive tools for CHD risk, which incorporate HDL-C and total cholesterol, but not LDL-C. (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach", section on 'Choosing a risk calculator'</a>.)</p><p>There is ongoing debate about the utility of apolipoprotein markers in the prediction of CHD risk. There is particular interest in the use of apoB and apolipoprotein A-1 (apoA-1). Overall, apoB and non-HDL cholesterol perform relatively similarly in terms of predicting CHD risk [<a href="#rid56">56</a>]. Use of the apoA-1/apoB ratio has also been examined. In an analysis of Framingham data, for example, multivariate analyses showed that ratios of total cholesterol/HDL, LDL/HDL, and apoA-1/apoB all performed similarly, and all were superior to any single measure alone [<a href="#rid52">52</a>]. Similarly, in an individual patient meta-analysis, the incorporation of apoB and apoA-1, lipoprotein(a), and lipoprotein-associated phospholipase A<sub>2</sub> mass added only slightly to CHD prediction [<a href="#rid57">57</a>].</p><p>The discussion of these additional tools for risk assessment is provided separately. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Family history'</a> and  <a class="medical medical_review" href="/z/d/html/5297.html" rel="external">"Coronary artery calcium scoring (CAC): Overview and clinical utilization"</a> and  <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Ankle-brachial index'</a> and  <a class="medical medical_review" href="/z/d/html/91564.html" rel="external">"Carotid intima-media thickness"</a> and  <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H685254601"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119659.html" rel="external">"Society guideline links: Assessment of cardiovascular risk"</a>.)</p><p class="headingAnchor" id="H2960596787"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction </strong>–<strong> </strong>Atherosclerotic cardiovascular disease (ASCVD) is common in the general population, affecting the majority of adults past the age of 60 years. While a general estimate of the relative risk for ASCVD can be approximated by counting the number of traditional risk factors present in a patient, a more precise estimation of the absolute risk for a first ASCVD event is desirable when making treatment recommendations for a specific individual. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multivariate risk models </strong>– A number of multivariate risk models have been developed for estimating the risk of cardiovascular events in apparently healthy, asymptomatic individuals based upon assessment of multiple variables  (<a class="graphic graphic_table graphicRef115308" href="/z/d/graphic/115308.html" rel="external">table 1</a>). While all of the risk models have advantages and disadvantages, no single risk model will be appropriate for all patients. The choice of a specific risk model for ASCVD risk assessment should be individualized based on patient-specific characteristics (eg, age, sex, ethnicity). However, our experts feel that the use of risk models that predict hard events (ie, death, myocardial infarction, stroke) are preferred over those that include other endpoints (ie, revascularization). (See <a class="local">'Multivariate risk models'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limitations </strong>– All of the risk models are subject to limitations, the most important of which is the ASCVD risk prediction over a defined period of time (usually 10 years) which may poorly characterize a person's long-term ASCVD risk, particularly in younger patients. Many individuals with a low 10-year risk, as calculated using the above models, will still have a high lifetime risk, as the largest driver of risk in most risk calculators is age. (See <a class="local">'Limitations of current vascular disease prediction models'</a> above and  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach", section on '10-year risk versus 30-year (lifetime) risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach </strong>– Our comprehensive approach to ASCVD risk assessment  (<a class="graphic graphic_algorithm graphicRef114544" href="/z/d/graphic/114544.html" rel="external">algorithm 1</a>) is discussed separately. The use of the risk models in decision making for the management of hypercholesterolemia or initiation of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy for primary prevention is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a> and  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain individuals with established ASCVD or ASCVD risk equivalents are known to be at high risk of recurrent cardiovascular events and should be treated with appropriate secondary prevention measures. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89.</a></li><li><a class="nounderline abstract_t">Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113:791.</a></li><li><a class="nounderline abstract_t">DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 2015; 162:266.</a></li><li><a class="nounderline abstract_t">Bazo-Alvarez JC, Quispe R, Peralta F, et al. Agreement Between Cardiovascular Disease Risk Scores in Resource-Limited Settings: Evidence from 5 Peruvian Sites. Crit Pathw Cardiol 2015; 14:74.</a></li><li><a class="nounderline abstract_t">Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375.</a></li><li><a class="nounderline abstract_t">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49.</a></li><li><a class="nounderline abstract_t">Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol 2014; 64:959.</a></li><li><a class="nounderline abstract_t">JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100 Suppl 2:ii1.</a></li><li><a class="nounderline abstract_t">Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837.</a></li><li><a class="nounderline abstract_t">D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180.</a></li><li><a class="nounderline abstract_t">National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.</a></li><li><a class="nounderline abstract_t">D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743.</a></li><li><a class="nounderline abstract_t">Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335:136.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336:1475.</a></li><li><a class="nounderline abstract_t">Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611.</a></li><li><a class="nounderline abstract_t">Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118:2243.</a></li><li><a class="nounderline abstract_t">Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311:1416.</a></li><li><a class="nounderline abstract_t">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 2014; 311:1406.</a></li><li><a class="nounderline abstract_t">Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013; 382:1762.</a></li><li><a class="nounderline abstract_t">Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e1082.</a></li><li><a class="nounderline abstract_t">McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol 2015; 66:1643.</a></li><li><a class="nounderline abstract_t">Yang X, Li J, Hu D, et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China). Circulation 2016; 134:1430.</a></li><li><a class="nounderline abstract_t">Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018; 391:1897.</a></li><li><a class="nounderline abstract_t">Khera A, Budoff MJ, O'Donnell CJ, et al. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator. Circulation 2018; 138:1819.</a></li><li><a class="nounderline abstract_t">Vassy JL, Lu B, Ho YL, et al. Estimation of Atherosclerotic Cardiovascular Disease Risk Among Patients in the Veterans Affairs Health Care System. JAMA Netw Open 2020; 3:e208236.</a></li><li><a class="nounderline abstract_t">Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.</a></li><li><a class="nounderline abstract_t">Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973.</a></li><li><a class="nounderline abstract_t">Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327:1267.</a></li><li><a class="nounderline abstract_t">Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291:2591.</a></li><li><a class="nounderline abstract_t">Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002; 105:310.</a></li><li><a class="nounderline abstract_t">Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ 2000; 320:705.</a></li><li><a class="nounderline abstract_t">Wallis EJ, Ramsay LE, Ul Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320:671.</a></li><li><a class="nounderline abstract_t">Sacco RL, Khatri M, Rundek T, et al. Improving global vascular risk prediction with behavioral and anthropometric factors. The multiethnic NOMAS (Northern Manhattan Cohort Study). J Am Coll Cardiol 2009; 54:2303.</a></li><li><a class="nounderline abstract_t">Ko DT, Sivaswamy A, Sud M, et al. Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations. CMAJ 2020; 192:E442.</a></li><li><a class="nounderline abstract_t">Pursnani A, Massaro JM, D'Agostino RB Sr, et al. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events. JAMA 2015; 314:134.</a></li><li><a class="nounderline abstract_t">Yadlowsky S, Hayward RA, Sussman JB, et al. Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk. Ann Intern Med 2018; 169:20.</a></li><li><a class="nounderline abstract_t">Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142:393.</a></li><li><a class="nounderline abstract_t">Ridker PM, Cook N. Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program. Circulation 2005; 111:657.</a></li><li><a class="nounderline abstract_t">Vasan RS, D'Agostino RB Sr. Age and time need not and should not be eliminated from the coronary risk prediction models. Circulation 2005; 111:542.</a></li><li><a class="nounderline abstract_t">Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486.</a></li><li><a class="nounderline abstract_t">Dalton JE, Perzynski AT, Zidar DA, et al. Accuracy of Cardiovascular Risk Prediction Varies by Neighborhood Socioeconomic Position: A Retrospective Cohort Study. Ann Intern Med 2017; 167:456.</a></li><li><a class="nounderline abstract_t">Wilson PW. Progressing from risk factors to omics. Circ Cardiovasc Genet 2008; 1:141.</a></li><li><a class="nounderline abstract_t">O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2022; 146:e93.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Curry SJ, Krist AH, et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320:272.</a></li><li><a class="nounderline abstract_t">Lin JS, Evans CV, Johnson E, et al. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320:281.</a></li><li><a class="nounderline abstract_t">Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2016; 133:849.</a></li><li><a class="nounderline abstract_t">Sandoval Y, Bielinski SJ, Daniels LB, et al. Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium. J Am Coll Cardiol 2020; 76:357.</a></li><li><a class="nounderline abstract_t">Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010; 45:907.</a></li><li><a class="nounderline abstract_t">Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol 1988; 4 Suppl A:5A.</a></li><li><a class="nounderline abstract_t">Arsenault BJ, Boekholdt SM, Kastelein JJ. Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol 2011; 8:197.</a></li><li><a class="nounderline abstract_t">Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298:776.</a></li><li><a class="nounderline abstract_t">Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993.</a></li><li><a class="nounderline abstract_t">Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307:1302.</a></li><li><a class="nounderline abstract_t">Ip S, Lichtenstein AH, Chung M, et al. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009; 150:474.</a></li><li><a class="nounderline abstract_t">Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol 2011; 58:457.</a></li><li><a class="nounderline abstract_t">Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307:2499.</a></li></ol></div><div id="topicVersionRevision">Topic 114029 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023892" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lifetime risk of developing coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461820" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25686167" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26102017" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Agreement Between Cardiovascular Disease Risk Scores in Resource-Limited Settings: Evidence from 5 Peruvian Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17726041" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222018" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25190228" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24667225" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603539" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prediction of coronary heart disease using risk factor categories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448281" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12485966" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18212285" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : General cardiovascular risk profile for use in primary care: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788299" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17615182" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573856" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299196" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997194" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24681960" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682252" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268611" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Statins: new American guidelines for prevention of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586774" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449133" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682885" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735391" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354651" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32662843" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Estimation of Atherosclerotic Cardiovascular Disease Risk Among Patients in the Veterans Affairs Health Care System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15680460" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12359975" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Framingham prediction rule is not valid in a European population of treated hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644971" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173150" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11804985" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710586" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710573" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958966" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Improving global vascular risk prediction with behavioral and anthropometric factors. The multiethnic NOMAS (Northern Manhattan Cohort Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32392491" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172893" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868850" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767617" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Relative importance of borderline and elevated levels of coronary heart disease risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699285" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699273" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Age and time need not and should not be eliminated from the coronary risk prediction models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11368702" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28847012" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Accuracy of Cardiovascular Risk Prediction Varies by Neighborhood Socioeconomic Position: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031555" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Progressing from risk factors to omics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35862132" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998297" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998301" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26801055" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703505" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20524075" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3179802" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21283149" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Lipid parameters for measuring risk of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699011" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903920" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Major lipids, apolipoproteins, and risk of vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22453571" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349632" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777740" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797450" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lipid-related markers and cardiovascular disease prediction.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
